Page 1

Arthrogen-CIA® Arthritogenic Monoclonal Antibody
Catalog # 53100
For Research Use Only - Not Human or Therapeutic Use

DESCRIPTION:

Mouse anti-type II collagen 5-clone monoclonal antibody cocktail kit with LPS from E. Coli
O111:B4APPLICATION:

Use for collagen antibody induced arthritis (CAIA) in mice

QUANTITY:

Cocktail: 10 mg/ml x 10 ml
LPS: 0.5 mg/ml x 7.5 ml

FORM:

A cocktail of 5 monoclonal antibodies dissolved in 0.05M phosphate buffered saline, pH 7.4
which recognize the conserved epitopes on various species of type II collagen: clone A2-10(IgG2a), F10-21 (IgG2a), D8-6 (IgG2a), D1-2G (IgG2b), and D2-112 (IgG2b). Clones A2-10,D1-2G, and D2-112 recognize individual epitopes clustered within the 167 amino acid peptide
fragment called LyC1 (124-290) of the CB11 fragment (124-402). Clones F10-21 and D8-6
recognize epitopes within the 83 amino acid peptide fragment called LyC2 (291-374) of theCB11 fragment.

SOURCE:

Mouse

CROSS-REACTIVITY:

Cross-reacts to most species of type II collagen including mouse, porcine, chick*, bovine,human, rat, monkey, rabbit, equine, and dog.
*D2-112 does not cross-react with chick type II collagen.

ANIMALS:

7-8 weeks or older, high responder mice: DBA/1, Balb/c, B10.RIII, C.B-17, scid/scid, or 129/Sv.
Low responder mice: C57BL/6 or C57BL/6 background. Sensitivity to CAIA may vary depending
on mouse vendor and facility. Specific pathogen free (SPF) housing conditions are strongly
recommended over conventional housing conditions as bacterial contamination may reduce theimmune response of the animals resulting in an attenuated arthritis. Therefore, running a pilot
study using a small number of animals before conducting a large-scale study is stronglyrecommended. Please contact Chondrex, Inc. customer support (support@chondrex.com) for
guidance regarding animals and housing conditions.

USAGE:

Administration of the monoclonal antibody cocktail by IV injection (i.e. tail vein) is recommended;however, intraperitoneal (IP) injection may also be used. Moreover, if LPS use is not desired,please note that the severity of arthritis tends to be lower.

PROTOCOLS:A.

Inducing arthritis with a combination of the monoclonal antibody cocktail and LPS in CAIA
susceptible mice (DBA/1, Balb/c, B10.RIII, C.B-17, scid/scid, or 129/Sv)
Day 0: Inject 1.5 mg of 5-clone cocktail by IV or IP injection.
Day 3: Inject 25-50 μg of LPS by IP injection.

© 2022 Chondrex, Inc. All Rights Reserved, 53100 7.1
16928 Woodinville-Redmond Rd NE Suite B-101
Woodinville, WA 98072

Phone: 425.702.6365 or 888.246.6373
Fax: 425.882.3094

www.chondrex.com
support@chondrex.com

Page 2

NOTE: Moderate to severe arthritis is observed on day 3-4 and peaks around day 7-10.
B.

Inducing arthritis with a combination of the monoclonal antibody cocktail and LPS in CAIA
low responder mice (C57BL/6 or C57BL/6 background)
Day 0: Inject 5 mg of 5-clone cocktail by IV or IP injection.
Day 3: Inject 25-50 μg of LPS by IP injection.
NOTE: Moderate to severe arthritis is observed on day 3-4 and peaks around day 7-10.
An injection of LPS on day 10-14 can be used to re-stimulate inflammatory arthritis.

C. Inducing arthritis with the monoclonal antibody cocktail without LPS in DBA/1 and Balb/cmice
Day 0: Inject 6-10 mg of 5-clone cocktail by IV injection.
NOTE: Arthritis can be observed on day 2-3. This protocol has not been confirmed in other
CAIA susceptible mouse strains such as B10.RIII, C.B-17, scid/scid, or 129/Sv mice.
STORAGE:-80°C

STABILITY:

2 years

NOTES:LPS is a common bacterial toxin and a potent stimulator of the immune system. The
recommended protocol for the Arthrogen-CIA® Cocktail utilizes LPS injection to trigger rapid
onset of severe arthritis with sub-arthritogenic doses of antibodies. The optimal dosage of LPS
can vary by mouse strain, animal vendor, and housing conditions. High doses of LPS can belethal for experimental animals, even 50 μg/mouse, depending on animal conditions. Therefore
Chondrex, Inc. recommends first performing a preliminary study without any antibody
administration to optimize LPS dosages (50 μg, 25 μg, and possibly 10 μg, testing each dosewith several mice) before conducting a large-scale CAIA study.

REFERENCES:

K. Terato et al. J. Immunol. 148: 2103-2108 (1992)
K. Terato et al. Autoimmunity 22: 137-147 (1995)
S. Yoshino et al. J. Immunol Methods 343: 49-55 (2009)© 2022 Chondrex, Inc. All Rights Reserved, 53100 7.1
16928 Woodinville-Redmond Rd NE Suite B-101
Woodinville, WA 98072

Phone: 425.702.6365 or 888.246.6373
Fax: 425.882.3094

www.chondrex.com
support@chondrex.com